arrow
T

Tim Illidge

University of Manchester
H指数:64
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

brentuximab vedotin联合化疗用于一线系统性间变性大细胞淋巴瘤的治疗:ECHELON-2研究5年随访的亚组分析

2025-08-010
OAAI
An International Lymphoma Radiation Oncology Group Study of Radiation Therapy for Bilateral Indolent Orbital Adnexal Lymphomas

国际淋巴瘤放射肿瘤学组关于双侧惰性眼附属器淋巴瘤放射治疗的研究

2025-03-140
PRE
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

ECHELON-2试验: brentuximab vedotin联合化疗治疗CD30-positive外周T细胞淋巴瘤的随机III期研究的5年结果

2022-03-01128
OAAI
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines
2020-08-0184
OAAI
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

免疫原性细胞死亡的定义、检测和解释的共识指南

2020-03-09740
OAAI
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Brentuximab vedotin联合化疗治疗CD30-positive外周T细胞淋巴瘤 (ECHELON-2): 一项全球性、双盲、随机、3期临床试验

LANCET
IF88.5
2019-01-01535
OAAI